Bidirectional Text Messaging for Measurement and Motivation of Medication Adherence in Hypertension, a Pilot Study
Launched by UNIVERSITY OF PENNSYLVANIA · May 19, 2016
Trial Information
Current as of May 23, 2025
Completed
Keywords
ClinConnect Summary
The goal of this pilot study is to test different approaches to monitor medication adherence in hypertension patients, leveraging the NIH-funded Way to Health platform. Patients with poor blood pressure control will be recruited from the University of Pennsylvania Health System and offered remote monitoring with electronic pill bottles or bidirectional text messaging. Our aim is to analyze and compare the effects of remote monitoring with electronic pill bottles versus bidirectional messaging on blood pressure reduction after 4 months.
Patients will be randomized 2:2:1 to Arm A (electronic...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Hypertension patients aged 18-75
- • At least two clinic visits in the past 12 months
- • Blood pressure readings in the last two visits that exceed recommended guidelines (150/90 or 140/90 if aged 21-59 yrs. or with diabetes or nondiabetic CKD).
- • Cellular phone with text messaging capabilities
- • Prescribed at least one medication for hypertension
- Exclusion Criteria:
- • Will not or cannot give consent
- • Diagnosed with dementia, end stage renal disease, cirrhosis, or metastatic cancer
About University Of Pennsylvania
The University of Pennsylvania, a prestigious Ivy League institution located in Philadelphia, is renowned for its commitment to advancing medical research and improving healthcare outcomes. As a clinical trial sponsor, the university leverages its extensive resources, interdisciplinary expertise, and cutting-edge facilities to conduct innovative studies across various therapeutic areas. With a focus on translating scientific discoveries into clinical applications, the University of Pennsylvania fosters collaborations among leading researchers, clinicians, and industry partners, ensuring rigorous trial design and adherence to ethical standards. Through its dedication to excellence in research and education, the university plays a pivotal role in shaping the future of medicine.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Trial Officials
Shivan Mehta, MD
Principal Investigator
University of Pennsylvania
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials